IDIOPATHIC PULMONARY FIBROSIS (IPF)

This Phase 2 trial tests an experimental inhaled medication called LTI-03 in about 120 people with idiopathic pulmonary fibrosis (IPF), a progressive lung disease that causes scarring and breathing difficulty. Participants will inhale LTI-03 or a placebo twice daily for 24 weeks.…

This phase IIb study tests three doses of AZD8965 against a placebo in 359 adults with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. The main goal is to see if AZD8965 can slow the decline in lung function over 24 weeks. Participants may also be taking standard IP…

This Phase II study tests a drug called BC006 in 96 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. The trial first checks safety in a small group, then randomly assigns patients to receive BC006 or a placebo every tw…

This early-stage trial is testing an inhaled form of nintedanib (called MNKD-201) in 24 people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. The study aims to see if the drug is safe and tolerable when breathed in, and how the body processes it. Partic…

This study looks at the long-term safety of an inhaled drug (AP01) for people with progressive lung scarring (pulmonary fibrosis). It is for those who already completed an earlier Avalyn Pharma study. About 340 participants will receive the drug and be monitored for side effects …

This Phase 3 trial tests a new drug called HEC585, taken once daily, to see if it can slow lung function decline in people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 472 adults aged 40 to 80 will be randomly assigned to receive HEC585, a plac…

This study tests an inhaled version of the drug nintedanib (called AP02) in people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 160 adults aged 40 and older who are not currently on IPF treatment will take either a low o…

This study tests whether quercetin, a natural compound found in many fruits and vegetables, can slow lung scarring and improve breathing in people with pulmonary fibrosis. Half of the 100 participants will take quercetin pills daily for 24 weeks, while the other half receive stan…

This study tests a new drug called TDI01 for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 508 adults in China will receive either TDI01 or a placebo to see if the drug helps slow lung function decline over 24 to 5…

This study tests a new drug, SV001, in 48 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. The main goal is to check if SV001 is safe and how the body processes it. Participants will receive either SV001 or a placebo, …

This study tests an experimental drug called SB17170 in 30 adults with moderate to severe idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants take either the drug or a placebo daily for 12 weeks. The main goal is to see if th…

This study tests an experimental oral drug called INS018_055 in 40 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. The main goal is to check the drug's safety over 12 weeks. Participants will be randomly assigned to r…

This study aims to see if bundling all routine tests and doctor visits into one coordinated hospital trip can save time for people with interstitial lung disease. About 152 adults with the condition will either receive standard care or the new streamlined approach. The goal is to…

This study tests whether bundling key tests like scans and lung function tests into a single, fast-tracked appointment can help people with suspected interstitial lung disease get a diagnosis sooner. About 92 adults will be randomly assigned to either the usual step-by-step testi…

This pilot study looks at how anti-fibrotic medications affect body composition in people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Researchers will use bioelectrical impedance analysis (BIA) and muscle ultrasound to track changes in muscle…

This study collects blood, airway, and urine samples from 2,000 healthy volunteers and people with lung diseases like COPD and pulmonary fibrosis. Researchers will compare samples to establish normal ranges and learn how genes change in lung disease. The goal is to better underst…

This study will examine chest CT scans from 500 adults with rheumatoid arthritis, connective tissue diseases, or idiopathic pulmonary fibrosis to better understand lung disease patterns. Researchers want to see which scan features are most common in rheumatoid arthritis-related i…